Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait.

Bristol Myers Squibb offers a 4.2% dividend yield and trades at a significant valuation discount (9.5x forward earnings) compared to peers (15-20x). While the dividend alone is modest, the main investment thesis centers on the company's turnaround potential. If its growth portfolio successfully offsets legacy drug patent expirations, the stock could experience substantial rerating upside. The company's sub-40% payout ratio suggests dividend safety in the near term.